All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Lisocabtagene maraleucel receives FDA approval for the second-line treatment of large B-cell lymphoma

Jun 28, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma/CLL

On June 24, 2022, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell product, for the treatment of relapsed or refractory large B-cell lymphoma in adult patients who have already received ≥1 line of systemic therapy. The approval is based on key data obtained from the phase III TRANSFORM and phase II PILOT studies (NCT03575351; NCT03483103). 1

The approval encompasses patients with diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma Grade 3B, who have:

  • Disease that is refractory to first-line chemoimmunotherapy or relapses within 1 year of first-line chemoimmunotherapy; or
  • Disease that is refractory to first-line chemoimmunotherapy or relapses after first-line chemoimmunotherapy that is not eligible for hematopoietic stem cell transplant.

Liso-cel has demonstrated deep and durable responses in these patient groups, while also exhibiting a tolerable safety profile. The approval comes shortly after news of the European Commission approval of liso-cel for the ≥3rd line treatment of certain forms of relapsed or refractory large B-cell lymphoma, as previously reported on the Lymphoma Hub.

  1. Bristol Myers Squib. U.S. FDA approves Bristol Myers Squibb’s CAR T cell therapy Breyanzi® for relapsed or refractory large B-cell lymphoma after one prior therapy. Published June 24, 2022. Accessed June 27, 2022.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox